Mostrando 1 - 20 Resultados de 131 Para Buscar '"América"', tiempo de consulta: 0.22s Limitar resultados
  1. 1
    “…OBJECTIVES: To evaluate five P. aeruginosa isolates from Central America that carried IMP-18- and/or VIM-2-encoding genes from the SENTRY Antimicrobial Surveillance Program (2017–2018). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Endemicity of Pseudomonas aeruginosa producing IMP-18 and/or VIM-2 MBLs from the high-risk clone ST111 in Central America
  2. 2
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
  3. 3
    “…METHODS: 2,582 GNB (1,630 Enterobacterales [ENT] and 952 nonfermentative-GNB) were consecutively collected (1/patient) from 56 medical centers located in Western Europe (W-EU; 22 centers in 10 nations), Eastern Europe (E-EU; 12 centers in 9 nations), Latin America (LATAM; 10 centers 6 nations), and the Asia-Pacific region (APAC; 12 centers in 8 nations) in 2019 and susceptibility (S) tested against ATM-AVI and comparators at a central laboratory by reference broth microdilution methods. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1261. Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019
  4. 4
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)
  5. 5
    “…This study evaluated the performance of the Vitek 2 Advanced Expert System (AES) confidence level report as a rapid tool for reporting antimicrobial susceptibility testing (AST) results for a challenging set of Enterobacterales isolates from North and Latin America. Enterobacterales isolates (n = 513) were tested by CLSI broth microdilution (BMD) and Vitek 2 (N802 and XN15 AST cards). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Performance of the Vitek 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales from North and Latin America
  6. 6
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)
  7. 7
    “…METHODS: A total of 13 752 Acb complex and 6467 S. maltophilia isolates were forwarded to a monitoring laboratory by 259 participating sites from the Asia-Pacific region, Latin America, Europe, and North America between 1997 and 2016. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)
  8. 8
    “…The highest rates of FLU-R isolates were seen in C. glabrata from North America (NA; 10.6%) and in C. tropicalis from the Asia-Pacific region (9.2%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016
  9. 9
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    257 In Vitro Activity of Meropenem/RPX7009, a Carbapenem/β-lactamase Inhibitor Combination Tested Against Contemporary Populations of Enterobacteriaceae and KPC-producing Strains
  10. 10
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1454 Antifungal Susceptibility Patterns of a Global Collection of Fungal Isolates and Polysorbate-80 Effect on the Susceptibility of the Antifungal Classes
  11. 11
    “…Significant increases were noted for MDR K. pneumoniae and Escherichia coli, polymyxin-resistant K. pneumoniae (2.0% to 5.5% overall), and aminoglycoside-resistant E. coli (7.0% to 18.0%) and K. pneumoniae (18.1% to 26.9%) over time in North America and Latin America. Carbapenemase-encoding genes were screened after 2007, and the occurrence of these genes was compared for 2007–2009 and 2014–2016. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program
  12. 12
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    250 Ceftazidime-avibactam Activity Tested Against a Large Collection of Enterobacteriaceae Isolates Collected in United States (USA) Hospitals in the 2011-2013 Period, Including Organisms Producing KPC- and CTX-M-variants
  13. 13
    “…Fungal surveillance isolates were collected from medical centers located in North America (30 sites; 37.9%), Europe (30 sites; 38.4%), Asia-Pacific (11 sites; 14.7%), and Latin America (6 sites; 9.0%). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2043. In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type
  14. 14
    “…[Figure: see text] METHODS: A total of 77 CAU collected (1/patient) in 2017–2022 from 12 medical centers in North America (NA; n=22; 6 centers), Europe (EU; n=32; 4 centers), Asia-Pacific (AP; n=1; 1 centers), and Latin America (LA, n=22; 1 centers) were identified by MALDI-TOF MS and tested by CLSI broth microdilution. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1948. Rise of Candida auris Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents against C. auris Causing Invasive Infections
  15. 15
    “…[Figure: see text] METHODS: C. albicans (CA; 233 isolates; 46.6%), C. glabrata (CG; 102; 20.4%), C. parapsilosis (CP; 82; 16.4%), C. tropicalis (CT; 41; 8.2%), C. krusei (CK; 18; 3.6%), C. dubliniensis (CD; 15; 3.0%), and C. auris (CARS; 9; 1.8%) isolates were collected (1/patient) in 2022 from 52 medical centers located in Europe (EU; n=203; 19 centers), North America (NA; n=167; 14 centers), Asia-Pacific (AP; n=63; 8 centers), and Latin America (LA, n=67; 7 centers), identified by MALDI-TOF MS and/or sequencing and tested by CLSI broth microdilution. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
  16. 16
    “…[Figure: see text] METHODS: A total of 1045 CGLA collected (1/patient) in 2014–2021 from 58 medical centers located in North America (NA; n=459; 20 centers), Europe (EU; n=396; 23 centers), Asia-Pacific (AP; n=130; 10 centers), and Latin America (LA, n=60; 5 centers) were identified by MALDI-TOF and/or sequencing and tested by CLSI broth microdilution. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
  17. 17
    “…[Figure: see text] METHODS: A total of 846 AFM collected (1/patient) in 2017–2021 from 44 medical centers located in North America (NA; n=282; 18 centers), Europe (EU; n=449; 17 centers), Asia-Pacific (AP; n=102; 8 centers), and Latin America (LA, n=13; 1 center) were identified by MALDI-TOF MS and/or sequencing and tested by CLSI broth microdilution. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
  18. 18
    “…Although there was no evidence for an increasing frequency of NWT strains among A. fumigatus isolates from North America, Latin America or the Asia-Pacific region, we confirm an increase in the rate of NWT strains to all three triazoles among isolates from Europe. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi
  19. 19
    “…METHODS: Isolates from Europe (EU), North America (NA), Latin America (LA), and Asia-Pacific (APAC) were identified by MALDI-TOF and/or sequencing and tested by CLSI broth microdilution. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    868. In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations
  20. 20
    “…[Figure: see text] METHODS: 830 isolates were collected from Europe (EU; 40.2%), North America (NA; 31.6%), Asia-Pacific (APAC; 15.3%), and Latin America (LA; 12.9%), identified by MALDI-TOF and/or sequencing, and tested by CLSI broth microdilution. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1731. Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021
Herramientas de búsqueda: RSS